Jason Gong

859 total citations
16 papers, 674 citations indexed

About

Jason Gong is a scholar working on Urology, Rheumatology and Molecular Biology. According to data from OpenAlex, Jason Gong has authored 16 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Urology, 7 papers in Rheumatology and 4 papers in Molecular Biology. Recurrent topics in Jason Gong's work include Urinary Bladder and Prostate Research (8 papers), Pelvic floor disorders treatments (7 papers) and Gastroesophageal reflux and treatments (3 papers). Jason Gong is often cited by papers focused on Urinary Bladder and Prostate Research (8 papers), Pelvic floor disorders treatments (7 papers) and Gastroesophageal reflux and treatments (3 papers). Jason Gong collaborates with scholars based in United States, France and Belgium. Jason Gong's co-authors include Zhonghong Guan, Martin Carlsson, Jon D. Morrow, Franklin Sun, Karen R. Reeves, Kathryn Williams, Clare B. Billing, Steven A. Kaplan, Sender Herschorn and Marina Brodsky and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and IEEE Journal of Solid-State Circuits.

In The Last Decade

Jason Gong

16 papers receiving 654 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jason Gong United States 11 459 396 232 132 87 16 674
Daniela Marschall‐Kehrel Germany 13 570 1.2× 464 1.2× 274 1.2× 22 0.2× 95 1.1× 27 697
Jukka Häkkinen Finland 17 426 0.9× 214 0.5× 74 0.3× 20 0.2× 68 0.8× 29 787
Tove Holm‐Larsen Denmark 11 218 0.5× 118 0.3× 68 0.3× 37 0.3× 59 0.7× 30 339
Denis Comet France 9 192 0.4× 81 0.2× 44 0.2× 29 0.2× 54 0.6× 25 348
Adolfo Casabé Argentina 18 545 1.2× 127 0.3× 15 0.1× 14 0.1× 63 0.7× 34 1.1k
C. Jeandel France 9 37 0.1× 39 0.1× 24 0.1× 63 0.5× 80 0.9× 54 277
Milena N. Mareva United States 8 86 0.2× 76 0.2× 135 0.6× 38 0.3× 30 0.3× 8 472
Önder Kayıgίl Türkiye 12 199 0.4× 130 0.3× 40 0.2× 9 0.1× 169 1.9× 76 474
Sebastian Sorsaburu United States 14 231 0.5× 59 0.1× 18 0.1× 8 0.1× 15 0.2× 20 543
Kathryn Anastassopoulos United States 11 47 0.1× 9 0.0× 34 0.1× 20 0.2× 73 0.8× 32 422

Countries citing papers authored by Jason Gong

Since Specialization
Citations

This map shows the geographic impact of Jason Gong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Gong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Gong more than expected).

Fields of papers citing papers by Jason Gong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Gong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Gong. The network helps show where Jason Gong may publish in the future.

Co-authorship network of co-authors of Jason Gong

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Gong. A scholar is included among the top collaborators of Jason Gong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Gong. Jason Gong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ignatiadis, Michail, Carlos H. Barrios, François‐Clément Bidard, et al.. (2024). International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.. Journal of Clinical Oncology. 42(16_suppl). TPS1129–TPS1129. 2 indexed citations
2.
Piscitelli, Joseph, Micaela B. Reddy, Lance Wollenberg, et al.. (2024). Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration. Clinical Pharmacokinetics. 63(4). 483–496. 4 indexed citations
3.
Piscitelli, Joseph, Micaela B. Reddy, Lance Wollenberg, et al.. (2024). Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(3). 337–347. 1 indexed citations
4.
Li, Jerry, Yazdi K. Pithavala, Jason Gong, et al.. (2021). The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants. Clinical Pharmacokinetics. 60(10). 1303–1312. 7 indexed citations
5.
Gong, Jason, Christine L. Baker, Kelly H. Zou, et al.. (2016). A Pragmatic Randomized Trial Comparing Telephone-Based Enhanced Pharmacy Care and Usual Care to Support Smoking Cessation. Journal of Managed Care & Specialty Pharmacy. 22(12). 1417–1425. 19 indexed citations
6.
Savoj, Jafar, Fu-Tai An, Jason Gong, et al.. (2013). A Low-Power 0.5–6.6 Gb/s Wireline Transceiver Embedded in Low-Cost 28 nm FPGAs. IEEE Journal of Solid-State Circuits. 48(11). 2582–2594. 14 indexed citations
7.
DuBeau, Catherine E., Stephen R. Kraus, Tomas L. Griebling, et al.. (2013). Effect of Fesoterodine in Vulnerable Elderly Subjects with Urgency Incontinence: A Double-Blind, Placebo Controlled Trial. The Journal of Urology. 191(2). 395–404. 100 indexed citations
8.
Kaplan, Steven A., Claus G. Roehrborn, Jason Gong, Franklin Sun, & Zhonghong Guan. (2011). Add‐on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α‐blocker treatment for lower urinary tract symptoms. British Journal of Urology. 109(12). 1831–1840. 48 indexed citations
9.
Malhotra, Bimal, et al.. (2011). Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. British Journal of Clinical Pharmacology. 72(2). 257–262. 14 indexed citations
10.
Corcos, Jacques, J.C. Angulo, Alan D. Garely, et al.. (2011). Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Current Medical Research and Opinion. 27(5). 1059–1065. 11 indexed citations
11.
Goldman, Howard B., Jon D. Morrow, Jason Gong, Li‐Jung Tseng, & Tim Schneider. (2010). Early onset of fesoterodine efficacy in subjects with overactive bladder. British Journal of Urology. 107(4). 598–602. 9 indexed citations
12.
Kaplan, Steven A., Tim Schneider, Jenelle E. Foote, et al.. (2010). Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial. British Journal of Urology. 107(9). 1432–1440. 85 indexed citations
13.
Wyndaele, Jean‐Jacques, Evan R. Goldfischer, Jon D. Morrow, et al.. (2010). Patient‐optimized doses of fesoterodine improve bladder symptoms in an open‐label, flexible‐dose study. British Journal of Urology. 107(4). 603–611. 19 indexed citations
14.
Dmochowski, Roger R., Kenneth M. Peters, Jon D. Morrow, et al.. (2009). Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. Urology. 75(1). 62–68. 78 indexed citations
15.
Herschorn, Sender, Steven Swift, Zhonghong Guan, et al.. (2009). Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial. British Journal of Urology. 105(1). 58–66. 132 indexed citations
16.
Williams, Kathryn, et al.. (2007). A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion. 23(4). 793–801. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniela Marschall‐Kehrel Breakdown of academic impact, for papers by Jukka Häkkinen Breakdown of academic impact, for papers by Tove Holm‐Larsen Breakdown of academic impact, for papers by Denis Comet Breakdown of academic impact, for papers by Adolfo Casabé Breakdown of academic impact, for papers by C. Jeandel Breakdown of academic impact, for papers by Milena N. Mareva Breakdown of academic impact, for papers by Önder Kayıgίl Breakdown of academic impact, for papers by Sebastian Sorsaburu Breakdown of academic impact, for papers by Kathryn Anastassopoulos
Rankless by CCL
2026